Search clinical trials for: pramipexol

Total 137 results

Boehringer Ingelheim

Completed

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

Early Parkinson Disease (Early PD)

United States, Argentina, Austria, Czech Republic, Finland, Germany, Hungary, India, Japan, Malaysia, Russian Federation, Slovakia, Taiwan, Ukraine
Boehringer Ingelheim

Completed

Pivotal Study in Advanced Parkinsons Disease Patients

Parkinson Disease

Austria, Czech Republic, Hungary, India, Italy, Korea, Republic of, Philippines, Poland, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Boehringer Ingelheim

Terminated

Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome

Tourette Syndrome

United States, Germany
Boehringer Ingelheim

Completed

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

In Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets Pramipexole in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of Increasing Pramipexole Doses of Oral Extended Release (ER) Tablets in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease

Parkinson Disease

France, Germany, Netherlands
Boehringer Ingelheim

Completed

Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers

Healthy

China
Boehringer Ingelheim

Completed

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

Parkinson Disease

Japan
Boehringer Ingelheim

Completed

Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients

Parkinson Disease

China
Boehringer Ingelheim

Completed

Long-term Administration Study of SND 919 Tablets in Parkinson's Disease

Parkinson Disease
Boehringer Ingelheim

Completed

A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS.

Idiopathic Restless Legs Syndrome

Japan
First Affiliated Hospital of Zhejiang University
Hongguan biological pharmaceutical co.

Terminated

Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets (PLKS-BE)

Parkinson's Disease

China
Boehringer Ingelheim

Completed

The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa

Parkinson Disease

China
Dexa Medica Group

Completed

Bioequivalence Study of Two Formulations of Pramipexole Tablets 0.25 mg

Healthy

Indonesia
Boehringer Ingelheim

Completed

Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome

Restless Legs Syndrome

Japan
Sandoz

Completed

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

Parkinson's Disease

Korea, Republic of
King's College Hospital NHS Trust

Unknown

Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia?

Type 1 Diabetes Mellitus

United Kingdom
Northwell Health
Stanley Medical Research Institute

Completed

Cognitive Enhancement in Bipolar Disorder

Bipolar Disorder

United States
Abbott Products

Terminated

A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.

Advanced Stage Parkinson's Disease

Germany, Italy, Portugal
Boehringer Ingelheim

Completed

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

Parkinson Disease

United States, Austria, Finland, France, Germany, Italy, Japan, Spain, Sweden, United Kingdom
Boehringer Ingelheim

Completed

Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances

Depression | Restless Legs Syndrome

Finland, France, Germany, Ireland, Italy, Korea, Republic of, Spain, Sweden, United Kingdom
Augusta University
GlaxoSmithKline

Completed

SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole

Restless Legs Syndrome

United States
Boehringer Ingelheim

Completed

a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients

Parkinson Disease

China
Boehringer Ingelheim

Completed

Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients

Restless Legs Syndrome

Germany, Austria, Netherlands, Norway, Sweden
Oregon Health and Science University
Boehringer Ingelheim

Completed

Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease (DALI)

Parkinson's Disease

United States
Region Skane
Lund University

Completed

Pramipexole to Target "Anhedonic Depression" (PILOT-PRAXOL)

Anhedonia | Depression, Unipolar | Dysthymia | Depression, Bipolar

Sweden
Assistance Publique - Hôpitaux de Paris

Completed

Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus (GLIDKIR6-2)

Diabetes Mellitus

France
Virginia Commonwealth University
Alzheimer's Drug Discovery Foundation; University of Kansas

Completed

Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease

Alzheimer's Disease

United States
University of Pecs

Withdrawn

Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor

Essential Tremor

Hungary
Boehringer Ingelheim

Completed

Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome

Restless Legs Syndrome

Austria
Teva Pharmaceuticals USA

Completed

Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions

Healthy

United States
Boehringer Ingelheim

Completed

Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment

Parkinson Disease

Austria
Research Foundation for Mental Hygiene, Inc.

Terminated

Combined Treatment of Prolonged Exposure and Pramipexole for Posttraumatic Stress Disorder and Depression

PTSD | MDD

United States
Boehringer Ingelheim

Terminated

Pramipexole ER vs. Placebo in Fibromyalgia

Fibromyalgia

United States
Massachusetts General Hospital
National Institute of Mental Health (NIMH)

Completed

Effectiveness of Pramipexole for Treatment-Resistant Depression

Depression

United States
Boehringer Ingelheim

Completed

Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria

Tourette Syndrome

United States, Germany
Stanford University

Enrolling by invitation

Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)

Depression | Anxiety

United States
Boehringer Ingelheim

Completed

Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease

Parkinson Disease
Bennett, James P., Jr., M.D., Ph.D.

Completed

R(+)PPX High Dose Treatment of ALS

Amyotrophic Lateral Sclerosis

United States
Solvay Pharmaceuticals

Completed

SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

Early Stage Parkinson Disease

United States, Australia, Czech Republic, Estonia, France, Germany, India, Italy, Lithuania, Malaysia, Netherlands, Poland, Portugal, South Africa, Spain, Taiwan, Thailand, United Kingdom
Teva Pharmaceuticals USA

Completed

Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions

Healthy

United States
University of New Mexico
University of New Mexico Clinical and Translational Science Center

Completed

Non-Opioid Pramipexole and Pain

Chronic Pain

United States
Bennett, James P., Jr., M.D., Ph.D.
University of Pittsburgh

Completed

R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States
Boehringer Ingelheim

Completed

Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers

Healthy
Pharma Two B Ltd.

Completed

Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

Parkinson's Disease

United States, Israel
University of California, San Diego
National Institute of Mental Health (NIMH); New York State Psychiatric Institute

Not yet recruiting

Pramipexole to Enhance Social Connections

Depression | Anxiety Disorders | Anxiety | Social Disconnection

United States
Pharma Two B Ltd.

Completed

A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

Parkinson Disease | Early Parkinson's Disease

United States, Canada, Germany, Spain
Bennett, James P., Jr., M.D., Ph.D.
University of Pittsburgh; University of Nebraska

Temporarily not available

Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day

Amyotrophic Lateral Sclerosis

Search clinical trials for: pramipexol

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations